RT Journal Article
SR Electronic
T1 Preliminary evaluation of voluntary event cancellation as a countermeasure against the COVID-19 outbreak in Japan as of 11 March, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.12.20035220
DO 10.1101/2020.03.12.20035220
A1 Sugishita, Yoshiyuki
A1 Kurita, Junko
A1 Sugawara, Tamie
A1 Ohkusa, Yasushi
YR 2020
UL http://medrxiv.org/content/early/2020/03/16/2020.03.12.20035220.abstract
AB Background To control COVID-19 outbreak in Japan, sports and entertainment events were canceled in Japan for two weeks from 26 February to 11 March. It has been designated as voluntary event cancellation (VEC).Object This study predicts the effectiveness of VEC enduring and after its implementation.Method We applied a simple susceptible–infected–recovery model to data of patients with symptoms in Japan during 14 January to VEC introduction and after VEC introduction to 8 March. We adjusted the reporting delay in the latest few days.Results Results suggest that the basic reproduction number, R0, before VEC introduced as 2.50 with a 95% confidence interval (CI) was [2.43, 2.55] and the effective reproduction number, Rv, after VEC introduced as 1. 88; its 95% CI was [1.68,2.02].Discussion and Conclusion Results demonstrated that VEC can reduce COVID-19 infectiousness by 35%, but R0 remains higher than one.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are fully available without restriction.https://www.mhlw.go.jp/stf/houdou/houdou_list_202001.html.